OMass Therapeutics

Overview

Oxford-based biopharmaceutical company developing therapeutics for immunological and rare diseases using its proprietary OdyssION native mass-spectrometry drug-discovery platform, spun out of Oxford University research; raised a $100M Series B in 2022 with Northpond Ventures as a new investor.

Key Facts

Sector

Biotech / Pharmaceuticals

Focus Areas